{"id":"NCT02131233","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","officialTitle":"A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05-23","primaryCompletion":"2015-12-21","completion":"2016-12-19","firstPosted":"2014-05-06","resultsPosted":"2016-10-31","lastUpdate":"2019-01-30"},"enrollment":802,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infection"],"interventions":[{"type":"DRUG","name":"Reformulated Raltegravir","otherNames":[]},{"type":"DRUG","name":"Raltegravir","otherNames":[]},{"type":"DRUG","name":"TRUVADA™","otherNames":[]},{"type":"DRUG","name":"Placebo to Reformulated Raltegravir","otherNames":[]},{"type":"DRUG","name":"Placebo to Raltegravir","otherNames":[]}],"arms":[{"label":"Reformulated Raltegravir","type":"EXPERIMENTAL"},{"label":"Raltegravir","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily in combination with TRUVADA™ versus raltegravir 400 mg twice daily in combination with TRUVADA™ in HIV-1 infected, treatment-naive participants. The primary hypothesis being tested is that reformulated raltegravir 1200 mg once-daily is non-inferior to raltegravir 400 mg twice-daily, each in combination therapy with TRUVADA™, as assessed by the proportion of participants achieving HIV-1 ribonucleic acid (RNA) \\<40 copies/mL at Week 48.","primaryOutcome":{"measure":"Percentage of Participants Achieving <40 Copies/mL Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"Reformulated Raltegravir","deltaMin":88.9,"sd":null},{"arm":"Raltegravir","deltaMin":88.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28918877","29771789"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":531},"commonTop":["Headache","Nausea","Diarrhoea","Upper respiratory tract infection","Nasopharyngitis"]}}